240 related articles for article (PubMed ID: 36389748)
1. Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme.
Cai X; Chen Z; Huang C; Shen J; Zeng W; Feng S; Liu Y; Li S; Chen M
Front Immunol; 2022; 13():950917. PubMed ID: 36389748
[TBL] [Abstract][Full Text] [Related]
2. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
3. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
Front Immunol; 2021; 12():706936. PubMed ID: 34899682
[TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
Wang Z; Bao Z; Yan W; You G; Wang Y; Li X; Zhang W
J Exp Clin Cancer Res; 2013 Aug; 32(1):59. PubMed ID: 23988086
[TBL] [Abstract][Full Text] [Related]
6. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
[TBL] [Abstract][Full Text] [Related]
7. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
Front Oncol; 2022; 12():938679. PubMed ID: 35982954
[TBL] [Abstract][Full Text] [Related]
8. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
9. Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq.
Ahmed YB; Ababneh OE; Al-Khalili AA; Serhan A; Hatamleh Z; Ghammaz O; Alkhaldi M; Alomari S
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339384
[TBL] [Abstract][Full Text] [Related]
10. A Promising Glycolysis- and Immune-Related Prognostic Signature for Glioblastoma.
Wang F; Liu X; Jiang H; Chen B
World Neurosurg; 2022 May; 161():e363-e375. PubMed ID: 35144031
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
12. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
13. U3 snoRNA-mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild-type glioblastoma cells.
Dong W; Liu Y; Wang P; Ruan X; Liu L; Xue Y; Ma T; E T; Wang D; Yang C; Lin H; Song J; Liu X
CNS Neurosci Ther; 2023 Oct; 29(10):2811-2825. PubMed ID: 37066523
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
16. A new prognostic model for glioblastoma multiforme based on coagulation-related genes.
Zhou M; Deng Y; Fu Y; Liang R; Liu Y; Liao Q
Transl Cancer Res; 2023 Oct; 12(10):2898-2910. PubMed ID: 37969372
[TBL] [Abstract][Full Text] [Related]
17. Effects of Glycolysis-Related Genes on Prognosis and the Tumor Microenvironment of Hepatocellular Carcinoma.
Zheng JY; Liu JY; Zhu T; Liu C; Gao Y; Dai WT; Zhuo W; Mao XY; He BM; Liu ZQ
Front Pharmacol; 2022; 13():895608. PubMed ID: 35924040
[No Abstract] [Full Text] [Related]
18. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Paldor I; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
Front Immunol; 2022; 13():939523. PubMed ID: 36091049
[TBL] [Abstract][Full Text] [Related]
20. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
